Symptomatic presentation influences outcomes in pediatric restrictive cardiomyopathy
Related Experiment Video
Updated: Jul 11, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Melissa Lorenzo1, Aine Lynch1, Jenna Ashkanase2
1Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Insights
Children with restrictive cardiomyopathy (RCM) who show symptoms at diagnosis have a worse prognosis. Early identification of symptoms is crucial for timely heart transplant listing in pediatric RCM patients.
Area of Science:
- Pediatric Cardiology
- Cardiomyopathy Research
- Transplant Medicine
Background:
- Restrictive cardiomyopathy (RCM) in children typically carries a poor prognosis, often leading to death or heart transplantation within two years.
- Early diagnosis of RCM is becoming more common due to evolving screening practices, highlighting the need to optimize transplant timing.
Purpose of the Study:
- To compare outcomes between children with RCM presenting with and without clinical symptoms.
- To identify the prognostic significance of symptoms at diagnosis for pediatric RCM patients.
Main Methods:
- Retrospective cohort study of 25 pediatric RCM patients diagnosed between 2001 and 2018.
- Comparison of times to transplantation, death, and a composite of adverse cardiac events between symptomatic and asymptomatic groups.
Main Results:
- Asymptomatic patients had significantly better 2-year transplant-free survival (57% vs. 17%, p=0.03) and cardiac event-free survival (71% vs. 25%, p=0.01).
- Cardiac symptoms at presentation were an independent risk factor for heart transplant or death (HR 5.17, p=0.02).
Conclusions:
- Symptomatic pediatric RCM patients face significantly worse transplant-free and cardiac event-free survival.
- Cardiac symptoms are a critical negative prognostic marker, necessitating urgent consideration for heart transplant listing.
Introduction:
Children with restrictive cardiomyopathy (RCM) traditionally have a poor prognosis, with most patients either dying or requiring heart transplantation within 2 years of diagnosis. The development of symptoms in RCM suggests advanced disease. However, as screening practices evolve and lead to diagnosis of early disease, identifying appropriate timing of transplant listing becomes increasingly important. In this context we compared outcomes of children with RCM presenting with clinical symptoms to those asymptomatic at initial presentation.
Methods:
This retrospective cohort study included 25 patients with RCM presenting to a quaternary care center between 2001 and 2018. Times to transplantation, death, and a composite outcome of adverse cardiac events (CPR, cardioversion, inotropic support, mechanical ventilation, mechanical support, or heart transplant) were compared between those symptomatic and asymptomatic at presentation.
Results:
At 2 years following diagnosis, patients asymptomatic at presentation had a significantly better transplant-free survival at 57% compared to 17% for symptomatic patients (p = 0.03). Those asymptomatic at diagnosis also had significantly improved cardiac event-free survival at 71% compared to symptomatic patients at 25% (p = 0.01). In multivariable analysis, cardiac symptoms at presentation remained an independent risk factor for heart-transplant or death [hazard ratio 5.17 (1.28-20.85), p = 0.02].
Conclusion:
Patients with RCM who are symptomatic at time of diagnosis have significantly worse transplant-free survival and cardiac event-free survival. Given current practice variability in timing of transplant listing, the presence of any cardiac symptoms is an important negative prognostic marker and should prompt urgent transplant listing.
Related Concept Videos
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Myocarditis II: Clinical Features and Diagnostic Tests
Cardiomyopathy II: Dilated Cardiomyopathy
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

